/
ALEC
$2.08+$0.22 (+11.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$206.5M
111M shares
52-week range
$1.09 – $3.40
43% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.37%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-20.33
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.7M | $21.2M | $21.1M | $207.1M | $133.6M | $97.1M | $100.6M | $21.0M |
| Cost of revenue | $73.0M | $100.5M | $156.9M | $189.4M | $0 | $8.8M | $185.9M | $9.7M |
| Gross profit | −$45.4M | −$79.3M | −$135.8M | $17.7M | $133.6M | $88.2M | −$85.4M | $11.4M |
| Gross margin | -163.9% | -373.8% | -643.5% | 8.5% | 100.0% | 90.9% | -84.9% | 54.1% |
| R&D | $73.0M | $100.5M | $156.9M | $189.4M | $210.4M | $192.1M | $209.2M | $123.1M |
| Operating income | −$57.3M | −$114.4M | −$195.2M | −$37.4M | −$137.8M | −$151.7M | −$145.0M | −$145.8M |
| EBITDA | −$56.3M | −$109.5M | −$187.9M | −$28.0M | −$121.6M | −$116.3M | −$110.1M | −$133.1M |
| Net income | −$52.2M | −$105.4M | −$190.2M | −$36.3M | −$133.3M | −$130.4M | −$119.0M | −$142.9M |
| Net margin | -188.8% | -496.7% | -901.6% | -17.5% | -99.8% | -134.3% | -118.4% | -679.2% |
| EPS (diluted) | -0.76 | -1.62 | -2.45 | -0.45 | -1.62 | -1.56 | -1.23 | -1.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-0.88 | $-1.09–$-0.76 | 6 |
| 2027 | $26M | $-0.63 | $-0.80–$-0.44 | 6 |
| 2028 | $3M | $-0.69 | $-0.86–$-0.40 | 4 |
| 2029 | $2M | $-0.61 | $-1.35–$-0.31 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Alector, Inc. Common Stock
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
www.alector.com- Employees
- 103
- IPO / List date
- Feb 7, 2019
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALEC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,287,691 | $2.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALEC yet.
